Spatial metabolomics informs the use of clinical imaging for improved detection of cribriform prostate cancer
Abstract
Cribriform prostate cancer (crPCa) is associated with poor clinical outcomes, yet its accurate detection remains challenging due to the poor sensitivity of standard-of-care diagnostic tools. Here, we use untargeted spatial metabolomics to identify fatty acid biosynthesis as a key metabolic pathway enriched in crPCa epithelium. We also show that imaging tumor lipid metabolism using [1- 11 C]acetate PET/CT and proton magnetic resonance spectroscopy differentiates cribriform from noncribriform intermediate-risk prostate cancers in two prospective patient cohorts. These findings support the feasibility of using clinical metabolic imaging techniques as adjunctive tools for improving crPCa detection in clinical practice, with prospective studies in larger cohorts warranted to obtain definitive results.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (17)
Nikita Sushentsev
Department of Radiology, Addenbrooke’s Hospital and University of Cambridge
Gregory Hamm
Integrated BioAnalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca
Roido Manavaki
Department of Radiology, Addenbrooke’s Hospital and University of Cambridge
Mary A. McLean
Department of Radiology, Addenbrooke’s Hospital and University of Cambridge
Jonathan Birchall
Department of Radiology, Addenbrooke’s Hospital and University of Cambridge
Dmitry Soloviev
Lewis Group, School of Cancer Sciences, University of Glasgow
David Y. Lewis
Luigi Aloj
Department of Radiology, Addenbrooke’s Hospital and University of Cambridge
Lucy Flint
Integrated BioAnalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca
Aleksandr Zakirov
Department of Clinical Neurosciences, University of Cambridge
Ian G. Mills
Nuffield Department of Surgical Sciences, University of Oxford
Vincent J. Gnanapragasam
Department of Urology, Cambridge University Hospitals National Health Service Foundation Trust
Anne Y. Warren
Department of Pathology, Cambridge University Hospitals National Health Service Foundation Trust
Simon T. Barry
Richard J. A. Goodwin
Integrated BioAnalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca
Ferdia A. Gallagher
Department of Radiology, Addenbrooke’s Hospital and University of Cambridge
Tristan Barrett
Department of Radiology, Addenbrooke’s Hospital and University of Cambridge